Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Anthony@Pacific who wrote (3122)	11/6/2000 10:20:36 PM
From: out_of_the_loop	Read Replies (1) \| Respond to of 5582

You are wrong on this, Tony. Zicam works - I know doctors who recommend it to their patients. Since I am a shareowner, you may dismiss that, however, the research that has been done on it is sound and was just printed in an ENT Journal. No it was not THE ABSOLUTE BEST JOURNAL in the world, but the editorial staff includes people from Mayo Clinic, UCLA, Stanford and Penn, which are among the top ENT programs in the country. The paper passed their scrutiny so forgive me if I believe them and my colleagues over someone who primarily shortsells stocks for a living. The mechanisms regarding the common cold point of infection and the inflammatory mediators are better understood now than when you were arguing about the Eby stuff most likely with regard to Quigley.